Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose-escalating Phase 1 Open-label Safety Study of ST266 Given by Non-invasive Intranasal Trans-cribriform Delivery in Glaucoma Suspect Subjects Without Evidence of Glaucomatous Damage.

NCT03901781 is registered in ClinicalTrials.gov with Noveome Biotherapeutics, formerly Stemnion as lead sponsor.

NCT NCT03901781
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03901781 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose-escalating Phase 1 Open-label Safety Study of ST266 Given by Non-invasive Intranasal Trans-cribriform Delivery in Glaucoma Suspect Subjects Without Evidence of Glaucomatous Damage.
Lead sponsor
Noveome Biotherapeutics, formerly Stemnion
Phase
Phase 1
Overall status
Completed
Start date
October 23, 2019
Completion date
May 20, 2022
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ocular hypertension